Background B-type natriuretic peptides and N-terminal pro-B-type natriuretic peptides (NT-proBNP) have been suggested as being useful for the diagnosis of congestive heart failure. We have shown previously that changes in thyroid function are associated with changes in concentrations of other low molecular weight molecules. Therefore, the aim of this study was to assess whether similar changes occurred with NT-proBNP concentrations following treatment of thyroid dysfunction.
Introduction
Measurement of brain, or B-type, natriuretic peptide (BNP) used in conjunction with other clinical information is useful in establishing or excluding the diagnosis of congestive heart failure in patients with acute dyspnoea. 1 BNP is a prognostically robust tool for risk stra-ti¢cation across the spectrum of acute coronary syndromes and it can reliably predict the presence or absence of left ventricular dysfunction on echocardiogram. 2 In the largest study involving 3177 Framingham probands, BNP showed excellent negative predictive values for excluding severe systolic left ventricular (LV) dysfunction, but because positive predictive values were weak, it indicated that BNP was unsuitable for screening in the community or high-risk population. 3 The decrease of natriuretic peptides (NPs) following treatment of heart failure has been shown to correlate with clinical bene¢t, improvement of functional parameters such as ejection fraction and surrogate parameters of therapy success such as renin levels and a decrease in heart rate. 4, 5 A change in BNP levels may be associated with other conditions. Pulmonary disease resulting in right ventricular dysfunction leads to increased BNP values. 6 Kruger et al. 7 found a good correlation of BNP with right ventricular dysfunction but not with clinical outcome in 50 patients with pulmonary embolism. Other non-cardiac causes associated with elevated NPs are renal failure, ascitic cirrhosis, hyperaldosteronism, hypercortisolism, subarachnoid haemorrhage, chronic obstructive pulmonary disease, carcinoma of the lung, increasing age, gender (higher in women and in the elderly) 8 and lower body mass indices. 9 Although the exact mechanisms of BNP release are still unclear, its release seems to be stimulated by increased LV wall stress and volume expansion. 10 BNP is synthesized as a pro-hormone and is secreted by proteolytic cleavage. Finally, the biologically active part, BNP, and the larger aminoterminal part, N-terminal pro-B-type natriuretic peptide (NT-proBNP), are released in equimolar amounts in circulation. 8 The in vivo half life of BNP is 20 min, which is shorter than that of NT-proBNP, at about 2 h, 11 and absolute values of BNP are signi¢cantly lower than values of NT-pro-BNP despite equimolar secretion. NT-proBNP was also found to be the only independent predictor of disease for the New York Heart Association (NYHA) class I and NYHA class II and therefore may be a more discerning marker for the detection and evaluation of heart failure than BNP. 12 The actual function of BNP is thought to be cardioprotective through increasing natriuresis and diuresis, vasodilatation and direct inhibition of the sympathetic nervous system and the renin--angiotensin system. 13 Changes to these parameters have also been found in patients with thyroid dysfunction. Triiodothyronine decreases systemic vascular resistance by dilating the resistance arterioles of the peripheral circulation. 14 As a result of the decrease in systemic vascular resistance, the e¡ective arterial ¢lling volume falls, causing an increase in renin release and activation of the angiotensin--aldosterone axis. 15 This, in turn, stimulates renal sodium reabsorption, leading to an increase in plasma volume. Thyroid hormone also stimulates erythropoietin secretion. The combined action of these two is an increase in blood volume and preload, which further increases cardiac output. 16 We have already shown that changes in thyroid function are associated with alteration in the concentration of cystatin C through a possible metabolic rate mediated mechanism; 17 this study has assessed whether similar changes are re£ected with NT-proBNP concentrations, following treatment of hypo-and hyperthyroidism. Schultz et al. 18 have shown alterations of NT-proBNP levels across a range of thyroid dysfunctions. Our study assessed whether the previously observed alterations in NT-proBNP levels with thyroid dysfunction are consistent and tries to interpret the results in the light of more recently published data on biological variation of this analyte.
Subjects and methods
To see a signi¢cant di¡erence in the NT-proBNP levels between baseline hyperthyroid and hypothyroid groups (80% power and a signi¢cance level of 5%), a sample size of 10 per group was calculated using nQuery Advisor (version 4, Statistics Solutions). 18 Seventeen patients (12 women, 5 men, median age 51yrs, age range 24--77 years) with newly diagnosed biochemical hypothyroidism (thyroid stimulating hormone [TSH] 45.0 mU/L [reference interval 0.5--4.7 mU/L] and free thyroxine [fT4] o9 pmol/L [9--24 pmol/L]), and 21 patients (16 women, 5 men, median age 48 years, range 21--66 years) with newly diagnosed hyperthyroidism (TSHo0.05 mU/L, fT44 24 pmol/L and free triiodothyronine [fT3]45.3 pmol/ L [0.5--5.3 pmol/L]) had NT-proBNP measured at baseline and when they subsequently became euthyroid (TSHo4.8 pmol/L, fT4 9--24 pmol/L). Patients were sequentially recruited from the Endocrine outpatient clinic at Michael White Centre, Hull Royal In¢rmary over a three-month period. The enrolled patients did not have a history of coronary heart disease. Using Boston Criteria, 19 heart failure was clinically excluded in all participants at the initial and follow-up visit(s). Hypothyroid patients were treated with thyroxine 100 mg for six weeks. The four patients who were not rendered euthyroid on this regime became so when given 150 mg thyroxine for a further six weeks. Twelve of the hyperthyroid patients became euthyroid after receiving carbimazole 20 mg for six weeks. Five became hypothyroid at this stage; 100 mg thyroxine was added and they were euthyroid by week 12 on the combination. Two patients required an increase in their carbimazole dose to 40 mg after six weeks and became euthyroid by week18. All samples were taken, spun immediately and serum frozen at À201C, then batch analysed in a single run at the end of the study. The study gained local Ethics Committee approval and patients gave their written informed consent for participation.
All thyroid assays were performed on an Abbott Architect i4000 immunoassay analyser (Abbott Diagnostics Division, Maidenhead, Berkshire, UK). The NT-proBNP measurements were done using Biomedica NT-proBNP assay; this assay has a detection limit of 5 pmol/L at 95% B/Bo and an intra-assay coe⁄cient of variation (CV) of less than 4% at 666 pmol/L. The following values for NT-proBNP were provided by the kit manufacturer: o250 pmol/L negative result; 250--350 pmol/L borderline result; 4350 pmol/L positive result. Serum creatinine was measured on a Beckman LX20 instrument (Beckman Coulter UK Ltd, High Wycombe, UK).
Results
The Kolmogorov--Smirnov test, histograms and normal plots showed that the distribution of data (NT-proBNP values) in both hyper-and hypothyroid groups were non-Gaussian; this was also con¢rmed by the Shapiro--Wilk test (using GB-STAT version 9.0, Dynamic Microsystems, Inc). Non-parametric methods were therefore used to analyse the NT-proBNP data. SPSS for Windows (version 12, SPSS Inc) was used for statistical analysis, except where otherwise speci¢ed. The Mann--Whitney test was employed to compare NT-proBNP levels in the hypothyroid group versus the hyperthyroid group before and after treatment to euthyroidism; the test did not show any statistically signi¢cant di¡erence between NT-proBNP levels in the two groups either before (P ¼ 0.706) or after treatment (P ¼ 0.179). Using Wilcoxon signed-ranks test, the changes in NT-proBNP were compared before and after treatment in each of the two groups of patients. This showed a statistically signi¢cant rise in NT-proBNP concentrations in the hypothyroid group following treatment (Po0.001) (Figure1). The subjects'weights in the hypothyroid group did not signi¢cantly change after treatment to euthyroidism (mean weight 7SD before and after treatment: 74.8479.08 kg versus 74.1479.05 kg; P ¼ 0.417). There was a marginally signi¢cant overall fall in NT-proBNP levels in the hyperthyroid group of patients after they achieved euthyroidism (P ¼ 0.05) ( Figure 2 ). However, there was a signi¢cant weight gain in this group of patients following treatment to euthyroidism (mean weight7SD before and after treatment 72.27718.13 kg versus 74.78717.24 kg; Po0.05).
Discussion
The presented data show that hypothyroidism reversibly alters NT-proBNP concentrations. Positron-emission tomographic studies of oxygen consumption in patients with hypothyroidism have revealed that myocardial work e⁄ciency is lower than in normal subjects. 20 Also, with an increase in systemic vascular resistance and slowed diastolic relaxation and ¢lling, 21 a high incidence of heart failure in patients with hypothyroidism may be expected. However, it seems that other haemodynamic changes associated with hypothyroidism (i.e. a reduction of blood volume and a decrease in renin release) can o¡set these e¡ects and in practice heart failure is rare because the cardiac output is usually su⁄cient to meet the lowered demand for peripheral oxygen delivery. 22 It therefore seems more likely that the changes in NT-proBNP in this group are as a result of a metabolic rate mediated e¡ect on peptide production, as has been suggested previously with cystatin C. 17 While cardiac failure is certainly recognized in hyperthyroidism, in practice it is uncommon other than in the occasional patient with severe, longstanding hyperthyroidism who develops hyperthyroid cardiomyopathy or the so-called rate-related heart failure. 23 This may well help explain the baseline similarities between the hyper-and hypothyroid group. Also, given the known relationship between higher body mass index and lower natriuretic concentrations, 9, 24 it is surprising that the weight gain found in this group after treatment did not lead to a larger change in NT-proBNP concentrations than in the hypothyroid patients.
In an assessment of NT-proBNP biological variability, Wu et al. 25 suggest that a change of 90% for NT-proBNP is necessary before results of serially collected data can be considered statistically di¡erent, and week-to-week intra-individual biological variation of NT-proBNP is estimated to be 30% in patients with stable heart failure. 26 Although this study supports the changes in NT-proBNP with hypothyroidism, as demonstrated earlier by Schultz et al., 18 in the context of the bio-variability of this natriuretic peptide the magnitude of the observed changes presented here are unlikely to be as clinically relevant. In contrast to Schultz et al., who found four-fold higher levels of NT-proBNP in hyperthyroid subjects than in the ones with hypothyroidism, we did not observe a signi¢cant di¡erence between the baseline levels of NT-proBNP in the two groups. Apart from using di¡erent assays in the two studies ( 24, 27 The assumption of normality has signi¢cant implications on the statistical power and the results. Other distinguishing factors between the two studies that could be potential sources of bias are In conclusion, this study has shown that treating hypothyroidism to the euthyroid state is associated with a rise in NT-proBNP concentrations and that treating hyperthyroidism leads to a fall. These changes seem to be secondary to a metabolic rate-mediated e¡ect on peptide production. However, because of the high biological variation of NT-proBNP, the magnitude of these changes are likely to be of limited clinical relevance.
